EUDA Health Accelerates Longevity Strategy with Stem Cell Platform & Clinic

EUDA Health Holdings Limited has announced a significant acceleration of its longevity and regenerative medicine strategy. The company is launching a comprehensive stem cell therapy platform and establishing its first clinic in Shenzhen, China. This initiative involves upgrading an existing cGMP facility to create a state-of-the-art production and innovation center for stem cell treatments, integrating proprietary iPSC technology and advanced stem cell technologies from Japanese partners. Concurrently, EUDA has partnered to establish a new longevity clinic in Shenzhen, which will offer advanced stem cell and T-cell immunotherapies, AI-guided life cycle management, and integrated Eastern, Western, and functional medicine. The clinic aims to enhance longevity by slowing biological aging and strengthening immunity, supported by international partnerships. The CEO, Alfred Lim, stated that this integration of iPSC platform, expanded therapies, enhanced production capacity, and a comprehensive clinic creates an end-to-end regenerative ecosystem, positioning EUDA to capitalize on the growing longevity sector.